Getagraph.com logo
NASDAQ Composite: ( 0.65%) 16 795
S&P 500 Futures
(0.00%) 5 331.50 points
Dow Jones Futures
(-0.01%) 39 941 points
Nasdaq Futures
(-0.09%) 18 746 points
Oil
(-1.34%) $78.73
Gas
(1.24%) $2.79
Gold
(-0.74%) $2 420.50
Silver
(-1.87%) $31.82
Platinum
(-1.49%) $1 047.90
USD/EUR
(-0.07%) $0.920
USD/NOK
(-0.30%) $10.66
USD/GBP
(-0.11%) $0.786
USD/RUB
(-0.26%) $90.45

Aktualne aktualizacje dla Ocugen Inc [OCGN]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
Ostatnio aktualizowano20 geg. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

0.52% $ 1.920

KUPNO 139087 min ago

@ $0.657

Wydano: 14 vas. 2024 @ 22:30

Zwrot: 192.46%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: 6.16 %

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
Dzisiejszy wolumen 3.50M
Średni wolumen 9.85M
Kapitalizacja rynkowa 494.07M
EPS $0 ( 2024-05-14 )
Następna data zysków ( $-0.0600 ) 2024-08-19
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -8.35
ATR14 $0.00800 (0.42%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.74
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

Wolumen Korelacja

Długi: -0.25 (neutral)
Krótki: -0.73 (moderate negative)
Signal:(49.015) Neutral

Ocugen Inc Korelacja

10 Najbardziej pozytywne korelacje
QNST0.939
PVAL0.937
LFMDP0.935
RNA0.935
GRID0.933
DWLD0.932
AVO0.93
SG0.928
QFIN0.927
SHLD0.926
10 Najbardziej negatywne korelacje
UONEK-0.918
RMGC-0.904
PRTS-0.902
TTEC-0.902
ACAD-0.9
UONE-0.897
AGRX-0.895
EEIQ-0.895
NLSP-0.893
QNRX-0.892

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocugen Inc Korelacja - Waluta/Towar

The country flag -0.71
( moderate negative )
The country flag -0.77
( moderate negative )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.16
( neutral )
The country flag 0.60
( weak )

Ocugen Inc Finanse

Annual 2023
Przychody: $6.04M
Zysk brutto: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
Przychody: $6.04M
Zysk brutto: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
Przychody: $0
Zysk brutto: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej